(40 MMOL/L) POTASSIUM CHLORIDE IN 0.9% SODIUM CHLORIDE INJECTION USP 300 MG / 100 ML
POTASSIUM CHLORIDE : 300 MG / 100 ML SODIUM CHLORIDE : 900 MG / 100 ML · DIN 00786217 · BAXTER CORPORATION
Health Canada status: MARKETED
What is (40 MMOL/L) POTASSIUM CHLORIDE IN 0.9% SODIUM CHLORIDE INJECTION USP?
(40 MMOL/L) POTASSIUM CHLORIDE IN 0.9% SODIUM CHLORIDE INJECTION USP 300 MG / 100 ML contains POTASSIUM CHLORIDE : 300 MG / 100 ML SODIUM CHLORIDE : 900 MG / 100 ML. It is listed in the Health Canada Drug Product Database under DIN 00786217, held by BAXTER CORPORATION, supplied as LIQUID for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 21-Jan-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is (40 MMOL/L) POTASSIUM CHLORIDE IN 0.9% SODIUM CHLORIDE INJECTION USP used for?
Fluid and electrolyte replenishment.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00786217 |
|---|---|
| Brand name | (40 MMOL/L) POTASSIUM CHLORIDE IN 0.9% SODIUM CHLORIDE INJECTION USP |
| Generic / active ingredient | POTASSIUM CHLORIDE : 300 MG / 100 ML SODIUM CHLORIDE : 900 MG / 100 ML |
| Manufacturer | BAXTER CORPORATION |
| Strength | 300 MG / 100 ML |
| Dosage form | LIQUID |
| Route of administration | INTRAVENOUS |
| Schedule | Ethical |
| ATC code | B05BB01 ELECTROLYTES |
| AHFS class | 40:12.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 21-Jan-2013 |
| Original market date | 1989-12-31 00:00:00 |
How is it administered?
Individualized by physician. Infusion rates generally should not exceed 10 mmol/h or 120 mmol/day. Max 20 mmol/h without cardiac monitoring. Intravenous use only.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at room temperature (15°C to 25°C). Avoid excessive heat.
How is it supplied?
1000 mL VIAFLEX Plus plastic containers.
Contraindications
Hypersensitivity; conditions where sodium, potassium, or chloride is detrimental; hyperkalemia; renal failure or impairment; conditions with potassium/sodium retention or edema.
Warnings and precautions
Risk of fluid/solute overload, pulmonary edema, and hyperkalemia. Never administer by IV push. High volume infusion may cause hyponatremia. Risk of air embolism if used in series.
What can be used instead?
Other Canadian products sharing ATC code B05BB01 ELECTROLYTES. 10 of 20 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| (20MMOL/L) POTASSIUM CHLORIDE IN 0.9% SODIUM CHLORIDE INJECTION USP | 150 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 00786209 |
| ISOLYTE S (MULTI-ELECTROLYTE INJECTION) | 530 MG / 100 ML | SOLUTION | B. BRAUN MEDICAL INC | MARKETED | DIN 01931628 |
| ISOLYTE S PH 7.4 (MULTI-ELECTROLYTE INJECTION) | 820 MCG / 100 ML | SOLUTION | B. BRAUN MEDICAL INC | MARKETED | DIN 01931679 |
| LACTATED RINGER'S INJECTION | 3.1 MG | SOLUTION | ICU MEDICAL CANADA INC | MARKETED | DIN 00039470 |
| LACTATED RINGER'S INJECTION USP | 20 MG / 100 ML | SOLUTION | B. BRAUN MEDICAL INC | MARKETED | DIN 01931636 |
| LACTATED RINGER'S INJECTION, USP | 310 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 00061085 |
| PLASMA-LYTE A INJECTION | 30 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02339358 |
| POTASSIUM CHLORIDE IN LACTATED RINGER'S INJECTION | 20 MG / 100 ML | LIQUID | BAXTER CORPORATION | MARKETED | DIN 02243421 |
| POTASSIUM CHLORIDE IN SODIUM CHLORIDE INJECTION USP | 450 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02269414 |
| (40 MMOLS/L) POTASSIUM CHLORIDE IN LACTATED RINGER'S INJECTION USP | 310 MG / 100 ML | SOLUTION | BAXTER CORPORATION | CANCELLED POST MARKET | DIN 02246134 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Request a quote for (40 MMOL/L) POTASSIUM CHLORIDE IN 0.9% SODIUM CHLORIDE INJECTION USP
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.